Get the Stockscreener App
5.67
4.42%
0.24
After Hours:
5.55
-0.12
-2.12%
Cero Therapeutics Holdings Inc stock is traded at $5.67, with a volume of 54,737.
It is up +4.42% in the last 24 hours and down -29.12% over the past month.
CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy. Its lead molecule is CER-1236, an autologous T-cell product that targets a novel tumor antigen, TIM-4 ligand.
See More
Previous Close:
$5.43
Open:
$5.47
24h Volume:
54,737
Relative Volume:
0.05
Market Cap:
$6.83M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+16.19%
1M Performance:
-29.12%
6M Performance:
-98.61%
1Y Performance:
-99.83%
1-Day Range:
$5.45
$5.71
1-Week Range:
$4.85
$5.71
52-Week Range:
$4.2701
$17,908.00
Cero Therapeutics Holdings Inc Stock (CERO) Company Profile
Name
Cero Therapeutics Holdings Inc
Sector
Industry
Phone
650-407-2376
Address
201 HASKINS WAY, SOUTH SAN FRANCISCO
Compare CERO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CERO
Cero Therapeutics Holdings Inc
|
5.67 | 6.55M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
391.36 | 100.82B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
461.24 | 60.45B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
575.06 | 60.69B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
752.32 | 46.32B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
327.20 | 36.58B | 3.81B | -644.79M | -669.77M | -6.24 |
Cero Therapeutics Holdings Inc Stock (CERO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-23-25 | Upgrade | D. Boral Capital | Hold → Buy |
Cero Therapeutics Holdings Inc Stock (CERO) Latest News
Risk Analysis: Should you avoid CERo Therapeutics Holdings Inc Equity Warrant stock right now2025 Sector Review & Daily Stock Trend Reports - خودرو بانک
Insider Sell: Will CERo Therapeutics Holdings Inc Equity Warrant outperform small cap indexes2025 Major Catalysts & Free Fast Entry Momentum Trade Alerts - خودرو بانک
Profit Review: Does Cass Information Systems Inc. have a competitive edgeStop Loss & Weekly High Conviction Ideas - خودرو بانک
Value Recap: How does CERo Therapeutics Holdings Inc score in quality rankings2025 Market Overview & Weekly High Return Stock Forecasts - خودرو بانک
Analyst Calls: Whats CERo Therapeutics Holdings Incs historical return2025 Growth vs Value & Technical Confirmation Alerts - خودرو بانک
Aug Ideas: Is CERo Therapeutics Holdings Inc likely to announce a buybackGap Down & Daily Technical Forecast Reports - خودرو بانک
Block Trades: Can CERo Therapeutics Holdings Inc Equity Warrant outperform in the next rallyJuly 2025 Summary & Reliable Intraday Trade Alerts - خودرو بانک
Breakouts Watch: Is CERo Therapeutics Holdings Inc Equity Warrant benefiting from interest rate changesWeekly Stock Recap & Reliable Volume Spike Alerts - خودرو بانک
Bank Watch: Is CERo Therapeutics Holdings Inc exposed to currency risks2025 Key Highlights & AI Powered Market Entry Ideas - خودرو بانک
Chipmakers Recap: Can CERo Therapeutics Holdings Inc outperform in the next rally2025 Retail Activity & Stock Portfolio Risk Management - خودرو بانک
EV Market: What drives UVSP’s stock priceInsider Buying & Accurate Intraday Trading Signals - خودرو بانک
Can CERo Therapeutics Holdings Inc deliver alphaWeekly Profit Summary & Community Trade Idea Sharing Platform - خودرو بانک
Aug Closing: What are analysts price targets for CERo Therapeutics Holdings IncWeekly Trend Report & Free Weekly Chart Analysis and Trade Guides - خودرو بانک
Aug Analyst Calls: Is CERo Therapeutics Holdings Inc.’s growth already priced inTrade Risk Summary & Weekly Market Pulse Alerts - خودرو بانک
Trade Recap: Can CERo Therapeutics Holdings Inc deliver consistent dividends2025 Market Outlook & Fast Moving Stock Trade Plans - خودرو بانک
Buyback Watch: Can CERo Therapeutics Holdings Inc be recession proof2025 Price Targets & Verified Stock Trade Ideas - خودرو بانک
CERo Therapeutics secures key patent protection for cancer therapy By Investing.com - Investing.com Australia
Is CERo Therapeutics Holdings Inc. likely to announce a buybackEarnings Recap Summary & Weekly Sector Rotation Insights - Lancaster City Council
Top 3 Health Care Stocks You'll Regret Missing In Q3 - Benzinga
CERo Therapeutics secures key patent protection for cancer therapy - Investing.com
CERo Therapeutics Receives Notice of Allowance from U.S. Patent and Trade Office on Composition of Matter and Method of Use for CER-1236 in Cancer with Expected Protection Through 2041 - The Manila Times
CERo Therapeutics Receives Notice of Allowance from U.S. - GlobeNewswire
Momentum Screeners Rank CERo Therapeutics Holdings Inc. Equity Warrant in Top 5 TodayFed Meeting & Weekly High Conviction Trade Ideas - beatles.ru
CERo Therapeutics Faces Nasdaq Delisting Risk - MSN
CERo Therapeutics Holdings Inc. Volume Confirms Breakout — Analysts BullishJuly 2025 Update & Community Verified Trade Alerts - beatles.ru
CERo Therapeutics Holdings Inc. Equity Warrant Stock Fails to Break Resistance Traders React2025 Technical Patterns & Free Low Drawdown Momentum Trade Ideas - beatles.ru
CERo Therapeutics administers second dose in AML clinical trial By Investing.com - Investing.com South Africa
Published on: 2025-09-08 20:17:23 - beatles.ru
CERo Therapeutics administers second dose in AML clinical trial - Investing.com
CERo Therapeutics Holdings Inc. Price Holds Above Key Fib Level2025 Market Sentiment & Risk Adjusted Buy/Sell Alerts - beatles.ru
CERo Therapeutics advances Phase 1 CER-1236 trial with dose intensification in AML - MarketScreener
CERo Therapeutics Announces Dose Intensification in Phase 1 Study of CER-1236 in Acute Myeloid Leukemia - GlobeNewswire
First-Ever TIM-4 Targeting Cell Therapy: CERo Therapeutics Advances AML Treatment with Doubled Dose Protocol - Stock Titan
Can CERo Therapeutics Holdings Inc. maintain its current growth rate2025 Momentum Check & Precise Entry and Exit Recommendations - beatles.ru
Is CERo Therapeutics Holdings Inc. being accumulated by smart moneyWeekly Profit Analysis & Weekly Consistent Profit Watchlists - خودرو بانک
Is CERo Therapeutics Holdings Inc. stock a good pick for beginnersMarket Growth Summary & High Accuracy Swing Entry Alerts - خودرو بانک
Published on: 2025-09-05 23:15:37 - خودرو بانک
What are CERo Therapeutics Holdings Inc. Equity Warrant’s growth leversJuly 2025 Reactions & Weekly High Potential Alerts - خودرو بانک
FDA grants fast track designation to CERo’s leukemia therapy By Investing.com - Investing.com Canada
What’s CERo Therapeutics Holdings Inc.’s historical returnWeekly Profit Summary & Entry Point Confirmation Alerts - خودرو بانک
Published on: 2025-09-06 00:07:46 - خودرو بانک
Energy Moves: Is CERo Therapeutics Holdings Inc. stock overvalued or fairly pricedTrade Performance Summary & Community Verified Trade Alerts - خودرو بانک
How to manage a losing position in CERo Therapeutics Holdings Inc.July 2025 Action & Long-Term Growth Stock Strategies - Newser
Historical volatility pattern of CERo Therapeutics Holdings Inc. visualized2025 Institutional Moves & Growth Focused Entry Point Reports - Newser
Will CERo Therapeutics Holdings Inc. bounce back from current support2025 Technical Patterns & Safe Entry Momentum Stock Tips - Newser
How to track smart money flows in CERo Therapeutics Holdings Inc. Equity Warrant2025 Support & Resistance & Momentum Based Trading Signals - Newser
Will CERo Therapeutics Holdings Inc. Equity Warrant outperform its industry peers2025 Technical Overview & Comprehensive Market Scan Insights - خودرو بانک
Published on: 2025-09-05 13:18:23 - Newser
CERo Therapeutics Gets Fast Track Designation For Experimental Cancer Drug, But Stock Tumbles – Here’s What Happened - Stocktwits
Is CERo Therapeutics Holdings Inc.’s growth already priced inMarket Growth Summary & Weekly Watchlist of Top Performers - خودرو بانک
CERo Therapeutics’ CER-1236: A High-Conviction Biotech Play with Accelerated Regulatory Pathways and Transformative AML Potential - AInvest
Cero Therapeutics Holdings Inc Stock (CERO) Financials Data
There is no financial data for Cero Therapeutics Holdings Inc (CERO). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
0.77%
1.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):